John De Vos
LightNews LightNews
banner
jdevos.bsky.social
John De Vos
@jdevos.bsky.social
350 followers 380 following 240 posts

#StemCells Researcher | Director of the Cell Processing Facility
University of Montpellier - CHU of Montpellier | #StemCells #iPScells for #lung #CellTherapy |
Stem Genomics co-founder | President of the FSSCR

Videos
Biology 37%
Environmental science 10%
Posts Replies Media Videos

Reposted by John De Vos

Reposted by John De Vos

davidctomkins.bsky.social
David Tomkins 🦋 @davidctomkins.bsky.social · 1d
"This is the hard truth I want to land: climate does not care what’s trending. It’s not interested in Jeffrey Epstein, Gaza, or Greenland. There is no algorithmic mercy. Physics is physics, and it is getting more abrupt."
#climatecrisis #ElNino #auspol www.lyrebirddreaming.com/post/we-are-...
If Epstein is Trending, Why Isn’t +1.7°C?
The news cycle has become a hall of mirrors: Epstein, Trumpism, war, outrage, retribution. A thousand scandals designed to keep us anxious, tribal, and tired. We have to hold multiple truths at once: ...
www.lyrebirddreaming.com

Reposted by John De Vos

Reposted by John De Vos

jdevos.bsky.social
John De Vos @jdevos.bsky.social · 5d
FDA reflections on #CARTCells therapies and autoimmunity: the key challenge is finding the match between the right product and the right indication.

www.fiercebiotech.com/biotech/fda-...
FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases
As the first CAR-T treatment for an autoimmune disease dr | As the first CAR-T treatment for an autoimmune disease draws ever closer, the FDA’s Vinay Prasad, M.D., and colleagues have signaled a willi...
www.fiercebiotech.com

Reposted by John De Vos

apikorsim.bsky.social
Yosh @apikorsim.bsky.social · 5d
D. Mionet #Geopolitis manque terriblement 😭 si quelqu'un a des nouvelles parmi vous je suis preneur...
a close up of a sunflower with a red center
ALT: a close up of a sunflower with a red center
media.tenor.com

Reposted by Richard S.J. Tol, Dorothy Bishop, John De Vos , and 9 more

maxkozlov.bsky.social
Max Kozlov @maxkozlov.bsky.social · 10d
I'm at the Willard Hotel where I've been denied entry and kicked out of the Reclaiming Science event with NIH director Bhattacharya & other top agency leaders.

@jocelynkaiser.bsky.social and I registered for the event months ago yet were told capacity was full, even as they let in dozens of others.

jdevos.bsky.social
John De Vos @jdevos.bsky.social · 11d
😂

jdevos.bsky.social
John De Vos @jdevos.bsky.social · 11d
I love this!
alexis-verger.cpesr.fr Alexis Verger 🧬🧫🧪 @alexis-verger.cpesr.fr · 12d
Let's try this #AcademicSky

1 fav, 1 funny, strange, or unexpected scientific anecdote about a paper, a scientist, a fact, hoping that some will be new to you.

Reposted by John De Vos

alexis-verger.cpesr.fr
Alexis Verger 🧬🧫🧪 @alexis-verger.cpesr.fr · 12d
Let's try this #AcademicSky

1 fav, 1 funny, strange, or unexpected scientific anecdote about a paper, a scientist, a fact, hoping that some will be new to you.

Reposted by John De Vos

Reposted by John De Vos

Reposted by John De Vos

Reposted by John De Vos

Reposted by John De Vos

norionakatsuji.bsky.social
Norio Nakatsuji @norionakatsuji.bsky.social · 21d
[AI companies will fail. We can salvage something from the wreckage | AI (artificial intelligence) |The Guardian]

“AI is asbestos in the walls of our tech society, stuffed there by monopolists run amok. A serious fight against it must strike at its roots“

www.theguardian.com/us-news/ng-i...
AI companies will fail. We can salvage something from the wreckage | Cory Doctorow
AI is asbestos in the walls of our tech society, stuffed there by monopolists run amok. A serious fight against it must strike at its roots
www.theguardian.com

Reposted by John De Vos

Reposted by John De Vos

erictopol.bsky.social
Eric Topol @erictopol.bsky.social · 25d
Another major triumph for a refractory autoimmune disease—hemolytic anemia—through engineered T cells
@nejm.org
nejm.org/doi/full/10....
CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia | NEJM
In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is d...
nejm.org

Reposted by John De Vos

Reposted by John De Vos

Reposted by John De Vos

stemcellreports.bsky.social
Stem Cell Reports @stemcellreports.bsky.social · 26d
Ludovic Vallier, Stem Cell Reports Associate Editor, is attending Biotherapy Days 2026 in Toulouse, France 28-30 January 2026. Connect with him to discuss whether your research is a fit for publishing in Stem Cell Reports!

Reposted by Stefan Rahmstorf, John De Vos, Du Toit , and 6 more

zacklabe.com
Zack Labe @zacklabe.com · Jan 10
2025 was the hottest year on record for ocean heat content. Unfortunately, we now say this every year. 🥹

"In addition to setting a new record in 2025, the global
ocean continues to show sustained and intensified warming."

+ #OpenAccess Study: doi.org/10.1007/s003...
+ Data: www.ocean.iap.ac.cn
Bar graph showing global ocean heat content change in the upper 2000 m from the late 1950s through 2025. There is a long-term warming in the time series, which is using IAP/CAS data.

jdevos.bsky.social
John De Vos @jdevos.bsky.social · Jan 9
Other data regarding #CARTCell treatments in France. Interesting!

Source : buff.ly/k3Z9kDv

jdevos.bsky.social
John De Vos @jdevos.bsky.social · Jan 8
Number of #CARTCell treatments in France : rapidly increasing.

Source : buff.ly/k3Z9kDv

jdevos.bsky.social
John De Vos @jdevos.bsky.social · Jan 8
Solid tumor, allogeneic #CART alert 📣 : encouraging results from a phase I study using allogeneic IL-13Rα2 CAR-T cells in five people with recurrent high-grade glioma.

buff.ly/Q8RBlx4
News: Off-the-shelf CRISPR CAR-T tackles brain tumours - CRISPR Medicine
A first-in-human, phase I trial tested intrathecal delivery of CRISPR-Cas9-edited, allogeneic IL-13Rα2 CAR-T cells in five people with recurrent high-grade glioma. The single-centre study reports…
crisprmedicinenews.com

jdevos.bsky.social
John De Vos @jdevos.bsky.social · Jan 5
Allogeneic #CARTCells in phase Ib/II clinical trials in China for the treatment of relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL). Phase I study showed interesting results.

buff.ly/SKuRXC9
CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
SHANGHAI,Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted
news.futunn.com